spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Thrombocytopenia 

 HSMN NewsFeed - 13 Feb 2025
Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(k) Clearance, Offering a Fast and Raliable Way to Predict the Risk of Developing Severe Preeclampsia
Diagnostics FDA
 HSMN NewsFeed - 18 Sep 2024
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI(TM) (trastuzumab-strf), a biosimilar to Herceptin(R) (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2023
Sobi to Acquire CTI BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2022
Sobi to license loncastuximab tesirine from ADC Therapeutics
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2021
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
Biopharmaceuticals
 HSMN NewsFeed - 5 Nov 2021
SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting
Devices
 HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jun 2021
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jan 2021
Doptelet(R) (avatrombopag) approved in the EU for treatment of ITP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Nov 2020
Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Nov 2020
Sobi launch Doptelet(R) (avatrombopag) in Europe
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jan 2020
Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jan 2020
Provention Bio Appoints Jason Hoitt as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2019
Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2018
Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jul 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 May 2018
Apexigen Expands Leadership Team With Appointment Of Frances Rena Bahjat, Ph.D. Vice President, Discovery Research
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 May 2018
Beckman Coulter Launches the DxH 900 Hematology Analyzer
Devices Diagnostics Product Launch
 HSMN NewsFeed - 20 Mar 2018
Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin(R) Injection
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Feb 2018
Grifols HyperRAB(R) (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Dec 2017
Rigel Announces Departure of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Aug 2017
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Aug 2017
VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Rigel's New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2017
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara(R) (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Apr 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2016
IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2016
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox(R) for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Sep 2016
FDA Approves New AGGRASTAT(R) Product Format
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 May 2016
Medicure Files Application for New AGGRASTAT(R) Product Format
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Nov 2015
Akers Biosciences Appoints Medical Technology Specialist as CEO
Diagnostics Personnel
 HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Jul 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX(R) (bivalirudin)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jan 2015
Akers Expands U.S. Sales Efforts With Key Leadership Additions
Diagnostics Personnel
 HSMN NewsFeed - 18 Dec 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2014
Ligand Signs Multi-Program Captisol(R) License Agreement with Avion Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Jul 2014
Aqua Pharmaceuticals, LLC Announces the U.S. Food and Drug Administration (FDA) Approval of ACTICLATE(TM) (doxycycline hyclate USP) Tablets, 150 mg and 75 mg
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2014
Akers Biosciences Signs Agreement With Medline -- a Major US Distributor
Diagnostics Distribution
 HSMN NewsFeed - 13 Jun 2014
Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia
Biopharmaceuticals
 HSMN NewsFeed - 5 May 2014
FDA Approves Conversion of Soliris(R) (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2014
FDA Approves New Liquid Form Of Treatment For Patients With Acute Lymphoblastic Leukemia (ALL) As Part Of A Combination Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Mar 2014
Edison Pharmaceuticals Announces Initiation of EPI-743 Pearson Syndrome Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2013
The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Oct 2013
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Oct 2013
First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures
Biopharmaceuticals Interventional
 HSMN NewsFeed - 3 Oct 2013
Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 13 Sep 2013
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2013
Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jul 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Feb 2013
Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2012
Mylan Launches Generic Version of Qualaquin(R) Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall
 HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2012
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2012
Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Aug 2012
Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2012
Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO(TM) (taliglucerase alfa) For The Treatment Of Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Apr 2012
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2012
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Dec 2011
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2011
Soliris(R) (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2011
OptiScan Biomedical Receives CE Mark for OptiScanner Automatic Bedside Glucose Monitoring System
Devices Monitoring Regulatory
 HSMN NewsFeed - 17 Aug 2011
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jul 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada(TM)*) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2011
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2011
Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2011
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Dec 2010
Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery
Biopharmaceuticals Orthopaedic Surgery
 HSMN NewsFeed - 6 Dec 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2010
Paclitaxel Poliglumex (OPAXIO(R)) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2010
Ligand Announces Approval for Revolade(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Oct 2010
aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
Biopharmaceuticals Venture Captial
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2010
FDA Approves New Dosing for FASLODEX(R) (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jul 2010
Abraxis BioScience and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2010
ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Jun 2010
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2010
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2010
Dr. John Mendlein Joins aTyr Pharma as Executive Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2010
Comparative Trial of Canyon's Iprivask(R) (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2010
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2009
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2009
Allos Therapeutics' FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Aug 2009
FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2009
FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Mar 2009
European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 13 Feb 2009
IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2008
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2008
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Sep 2008
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Biopharmaceuticals Litigation
 HSMN NewsFeed - 3 Sep 2008
New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2008
New Data Shows Anticlotting Medicine, AGGRASTAT(R), Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, after Elective Coronary Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Aug 2008
FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Aug 2008
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2008
Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jul 2008
Banner Pharmacaps Receives FDA Approval for Valproic Acid Delayed Release Softgel Capsules
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2008
VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2008
Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
ABRAXANE(R) in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2008
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2008
Bayer Announces Availability of Reformulated Liquid Leukine(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2008
Medicure Comments on Positive AGGRASTAT Results Presented at the American College of Cardiology Annual Scientific Session
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2008
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2008
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2008
FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2008
Hospira Launches Generic Irinotecan Injection
Biopharmaceuticals Oncology Generics
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2008
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jan 2008
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jan 2008
Barr Confirms Patent Challenge of Argatroban(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 28 Dec 2007
Encysive Pharmaceuticals Announces Patent Infringement Lawsuit Against Barr Laboratories
Biopharmaceuticals Litigation
 HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 17 Dec 2007
Otsuka Pharmaceutical Acquires Rights to IV Busulfex From PDL BioPharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2007
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Dec 2007
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2007
Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Oct 2007
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2007
Ligand Earns Milestone Payment as Wyeth Submits European Market Authorization for Bazedoxifene
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 11 Oct 2007
AkaRx and MGI PHARMA Announce Closing of Development and License Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Oct 2007
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2007
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 10 Sep 2007
Aspreva Provides Update On Lupus Nephritis Development Program
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2007
INNOVIVE Pharmaceuticals Acquires Exclusive Rights to Develop and Commercialize Tamibarotene in Europe
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 2 Sep 2007
Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2007
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 28 Aug 2007
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology
 HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2007
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 20 Jul 2007
Journal of Clinical Oncology Publishes Data on ZOLINZA(TM) (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
TargeGen, Inc. Closes $40M Series 'D' Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jul 2007
Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jun 2007
Health Canada approves new chemotherapy treatment for patients with metastatic colorectal cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jun 2007
Pivotal Phase III Trial Showed PROMACTA(R) (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2007
INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine(R) (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
ImmunoGen, Inc. Announces Clinical Data Reported at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Oncology Urology
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 16 May 2007
Genzyme Announces Positive Initial Observations in Trial Evaluating Novel Oral Treatment for Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 May 2007
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Apr 2007
Ligand Names John P. Sharp Chief Financial Officer
Biopharmaceuticals Personne
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Apr 2007
BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2007
FDA approves Cangene's HepaGam B(TM) for a second indication; for use in hepatitis B-positive liver transplant recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Apr 2007
FDA approves Cangene's HepaGam B(TM) for a second indication; for use in hepatitis B-positive liver transplant recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2007
Genta Appeals FDA Decision on Genasense(R) in CLL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2007
Baxter Announces FDA Approval Of Ceprotin For Severe Congential Protein C Deficiency
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Mar 2007
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2007
Ligand Pharmaceuticals Completes Sale of AVINZA to King Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Feb 2007
Phase 2 Results of Genasense(R) Plus Chemotherapy in Advanced Prostate Cancer Reported at Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2007
Clinical Data Supporting Development of ChemGenex's Ceflatonin(R) in Imatinib-Resistant CML Published in Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2007
Genta Completes Response to EMEA List of Outstanding Issues for Genasense(R) Marketing Authorization Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2007
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jan 2007
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jan 2007
Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
ELAD(R) Bioartificial Liver Trial in China Achieves Significance at Halfway Point
Devices
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
New Evoltra(R) Data Shows Impressive Response and Survival Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Nov 2006
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2006
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 9 Nov 2006
Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2006
Pharmion Corporation Announces Enrollment of First Patient Into Vidaza(R) Patient Registry
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Vion Pharmaceuticals Presents Initial Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Patients With Relapsed or Refractory Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Oct 2006
FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Oct 2006
GSK's New Flu Vaccine, FluLaval(TM), Provides Americans With a New Option for Fighting the Flu
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
FDA Grants Priority Review for ARIXTRA(R) (fondaparinux sodium) in the Treatment of Acute Coronary Syndromes
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Hollis-Eden Pharmaceuticals Provides Update on Bone Marrow Regeneration Program and Chemotherapy Indication
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2006
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(R)(Enoxaparin Sodium Injection) Vs. Unfractionated Heparin in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention (PCI)
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 17 Jul 2006
FDA Approves Lilly's Gemzar(R) For Ovarian Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 May 2006
MGI PHARMA Announces Commercial Availability of Dacogen(TM) (Decitabine) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 361

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 361 additional stories matching:
Thrombocytopenia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.